Advances in Cancer Photomedicine
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 27361
Special Issue Editors
Interests: photochemistry; photobiology; photomedicine; reactive oxygen species; free radicals; cell metabolism & bioenergetics; mitochondrial respiration and electron transport chain; nanomedicine; second harmonic generation from tissue; radiobiology; chemi/bio-luminescence in photomedicine
Special Issue Information
Dear Colleagues,
According to the World Health Organization (WHO), cancer claimed an estimated 9.6 million lives in 2018 (about 1 in 6 deaths was related to cancer) and is the second leading cause of death globally. By 2040, the projected number of cancer related deaths is expected to climb up to 16.4 million.
The current standards of care for cancer treatment in general include surgery, radiotherapy, chemotherapy, and immunotherapies. However, these modalities are not sufficient to curb the grim cancer statistics summarized above.
Cancer photomedicine, with photodynamic therapy of cancer (PDT) and photochemical internalization (PCI) as its most prominent representatives in the clinic, is currently underrated and mainly limited by the poor penetration of light into tissue.
Photomedical cancer treatments are cross-disciplinary, spanning synthetic chemistry, photochemistry, photobiology, bio- and nano-engineering, chemi-/bio-luminescence, photogenerated reactive oxygen species and redox systems, and clinical research, among other disciplines. In addition, several hybrid/combinatorial treatment modalities are emerging as of late.
This Special Issue aims to provide an overview of the state of the art in cancer photomedicine across disciplines and also provide an outlook into future trends and prospective clinical applications.
Dr. Theodossis A. Theodossiou
Dr. Mantas Grigalavicius
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- photomedicine
- photodynamic therapy
- photochemical internalization
- photogenerated ROS
- photochemistry
- chemistry
- bio-engineering
- nanoparticles
- clinical photomedicine
- chemi-/bio-luminescence